120 Euro Ne Kadar: Comparing GreenLight PVP and TURP for Prostate Treatment
This study evaluates the effectiveness of GreenLight High Performance System (HPS) 120-W photoselective vaporization of the prostate (PVP) against the standard transurethral resection of the prostate (TURP) for treating urinary symptoms. While the cost implications, such as understanding “120 Euro Ne Kadar” in different healthcare systems, are important considerations for patients, this research focuses on the medical outcomes of these two procedures.
The primary goal was to determine if PVP is as effective as TURP in relieving urinary symptoms and if it offers an advantage in reducing hospital stay duration. Researchers conducted a randomized controlled trial across multiple centers, comparing patients undergoing either monopolar TURP or PVP using the GreenLight HPS 120-W laser.
The study involved 139 participants who were randomly assigned to either TURP (70 men) or PVP (69 men). Over a 12-month follow-up period, various measurements were taken, including the International Prostate Symptom Score (IPSS), Euro-QOL questionnaire for quality of life, uroflowmetry to assess urinary flow, and the Danish Prostate Symptom Score Sexual Function Questionnaire. Sexual satisfaction and any adverse events were also recorded.
The results indicated that at 12 months, the median IPSS scores were similar between the two groups, with TURP at 5 (IQR: 3-8) and PVP at 6 (IQR: 3-9). Statistical analysis using the 95% confidence interval suggested that noninferiority of PVP to TURP in terms of symptom improvement could not be definitively proven based on the pre-defined margin. However, a significant difference was observed in hospital stay. The median hospital stay for the PVP group was 1 day (IQR: 1-2) compared to 2.5 days (IQR: 2-3.5) for the TURP group (p<0.0001), indicating a shorter hospital stay with PVP.
Uroflowmetry results and complication rates were comparable between both groups. Sexual outcomes showed a slight improvement in the PVP group, although this difference was not statistically significant.
In conclusion, this study did not confirm that 120-W GreenLight PVP is not inferior to TURP in improving prostate symptoms after one year. However, it did demonstrate that PVP is associated with a significantly shorter hospital stay. When considering treatment options, factors beyond just symptom relief and hospital stay, such as long-term outcomes and cost-effectiveness – which may lead patients to inquire “120 euro ne kadar” in their context – are also important for comprehensive decision-making in prostate treatment.